artificial tolerogenic dendritic cell-derived vesicles

Artificial Tolerogenic Dendritic Cell-Derived Vesicles (ACDV tolDC) are synthetic extracellular vesicles engineered from tolerogenic dendritic cells (tolDCs) using a high-pressure homogenization process. These vesicles retain the immunosuppressive and tolerance-inducing properties of their parent cells but offer improved scalability, stability, and production yield compared to live-cell therapies. In preclinical models of type 1 diabetes (T1D), ACDV tolDC demonstrated the ability to reduce T cell infiltration in pancreatic tissue, restore regulatory/cytotoxic T cell balance, preserve β-cell function, and delay or ameliorate disease onset. The therapeutic effect was superior to that of traditional tolDC therapy. This approach addresses key limitations of cellular immunotherapies—such as viability and manufacturing complexity—by providing a stable, potent vesicle-based alternative for immune modulation in autoimmune diseases like T1D[7][1].

Other names

artificial tolDC-derived vesiclesACDV tolDC